THE Pharmaceutical Benefits Advisory committee (PBAC) has recommended that 9-valent human papillomavirus (9vHPV) vaccine Gardasil 9 be made available as a designated vaccine for funding through the National Immunisation Program (NIP).
Recent research at Mebourne's Royal Women's Hospital and Victorian Cytology Service revealed broader protection (PD 14 Aug).
PBAC comments: pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Aug 17